Background: Mycobacterium seedling is rich in co-antigens and, a good immunomodulator with bidirectional immunomodulatory function.
Objectives: The present study aimed to explore whether the Mycobacterium vaccae vaccine can improve the incomplete immune recovery of acquired immunodeficiency syndrome (AIDS) patients.
Methods: According to the number of patients receiving human immunodeficiency virus (HIV) long-term treatment in the Ninth People’s Hospital of Chongqing, China, 100 patients with HIV-RNA quantitation of less than 103 cepies/ml, CD4 + T cell count less than 500/UL, and CD4+T cell count of more than 50/UL after 3 years of Haart treatment were selected. In total, they were randomly assigned to one of three groups, one group received an intramuscular injection of M. vaccae vaccine, one group received an intramuscular injection of growth hormone, and the last group received only a placebo injection. The levels and changes of naive T cells, Treg cells, total CD4+ T cells, T helper 1 (Th1), T helper 2 (Th2) cells, and interleukin 7 (IL-7) cytokine were measured at baseline and after 12, 48, and 50 weeks.
Results: After 48 weeks of treatment, the total CD4+T cells, Th1 cells, and naive T cells in AIDS patients increased, while IL-7 cytokines, Treg cells, and Th2 cells decreased in M. vaccae vaccine and growth hormone group. There was no change in the placebo group, indicating that M. vaccae vaccine and growth hormone can improve the immune function of AIDS patients. After treatment, in group A (M. vaccae vaccine), there was an increase in the total CD4+T cells, Th1 cells, and naive T cells as well as a decrease in Treg cells, Th2 cells, and IL-7 cytokines. The only significant difference between M. vaccae vaccine and growth hormone groups was a decrease in Th1 cells in the M. vaccae vaccine group. After a 12-week follow-up, it was found that there were no cases of secondary infection in the M. vaccae vaccine group, one case in the growth hormone group, and five cases in the placebo group, demonstrating that the secondary infection rate in M. vaccae vaccine and the growth hormone groups was lower than that in the control group.
Conclusion: The M. vaccae vaccine may decrease the levels of IL-7 as well as Treg and Th2 cells by increasing the levels of CD4+T cells, Th1 cells, and pure T cells in AIDS patients, leading to the improvement of immune reconstitution of AIDS patients to some extent.
Teng CW, He MR, Zhao YQ and Yang H. Effect of highly active antiretroviral therapy on body metabolism and T lymphocyte subpopulation in AIDS patients. J Guizhou Med Uni. 2019;44(06):712-20.
Yang X, Su B, Zhang X, Liu Y, Wu H, Zhang T. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders. J Leukoc Biol. 2020;107(4):597-612. doi: 10.1002/JLB.4MR1019-189R. [PubMed: 31965635].
Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol. 2012;2012:670957. doi: 10.1155/2012/670957. [PubMed: 22474480].
Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr. 2010;55(4):451-9. doi: 10.1097/qai.0b013e3181ec28ff. [PubMed: 21105259].
Engsig FN, Gerstoft J, Kronborg G, Larsen CS, Pedersen G, Roge B, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: A cohort study. BMC Infect Dis. 2010;10:318. doi: 10.1186/1471-2334-10-318. [PubMed: 21044307].
Reekie J, Kosa C, Engsig F, Monforte AD, Wiercinska-Drapalo A, Domingo P, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116(22):5306-15. doi: 10.1002/cncr.25311. [PubMed: 20661911].
Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747-51. doi: 10.1097/QAD.0b013e32834a40cd. [PubMed: 21750419].
Kolte L. Thymic function in HIV-infection. Dan Med J. 2013;60(4):B4622. [PubMed: 23651726].
Boyer Z, Palmer S. Targeting immune checkpoint molecules to eliminate latent HIV. Front Immunol. 2018;9:2339. doi: 10.3389/fimmu.2018.02339. [PubMed: 30459753].
Sabbatini F, Bandera A, Ferrario G, Trabattoni D, Marchetti G, Franzetti F, et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PLoS One. 2010;
(11):e14119. doi: 10.1371/journal.pone.0014119. [PubMed: 21124762].
Bourinbaiar AS , Batbold U , Efremenko Y , Sanjagdorj M , Botov D , Damdinpurev N, et al. Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed M. vaccae administered daily for one month. J Clin Tuberc Other Mycobact Dis. 2019;18:100141. doi: 10.1016/j.jctube.2019.100141. [PubMed: 31890902].
He MR, Chen ZF, Yang H, Cao YP, Xie LH, Xie XM. Impact of Mycobacterium vaccae vaccine on CD4 + T cell and CD8+ T cell counts and viral load in asymptomatic HIV-infected patients. Int J Med Lab. 2014;35(06):675-9.
Espert L, Beaumelle B, Vergne I.. Autophagy in Mycobacterium tuberculosis and HIV infections. Front Cell Infect Microbiol. 2015;5:49. doi: 10.3389/fcimb.2015.00049. [PubMed: 26082897].
Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 2020;64:1-12. doi: 10.1016/j.semcancer.2019.06.001. [PubMed: 31181267].
Nguyen TP, Shukla S, Asaad R, Freeman ML, Lederman MM, Harding CV et al. Responsiveness to IL-7 but not to IFN-alpha is diminished in CD4(+) T cells from treated HIV infected patients who experience poor CD4(+) T-cell recovery. AIDS. 2016;30(13):2033-42. doi: 10.1097/QAD.0000000000001161. [PubMed: 27191978].
Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D. Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. J Immunol. 2014;193(3):1047-54. doi: 10.4049/jimmunol. 1302936. [PubMed: 24958901].
Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14(4):307-8. doi: 10.1038/ni.2554. [PubMed: 23507634].
Natalini A, Simonetti S, Favaretto G, Peruzzi G, Antonangeli F, Santoni A, et al. OMIP-079: Cell cycle of CD4+ and CD8+ naïve/memory T cell subsets, and of Treg cells from mouse spleen. Cytometry A. 2021;99(12):1171-5. doi: 10.1002/cyto.a.24509. [PubMed: 34668313].
Appay V, Sauce D. Naive T cells: the crux of cellular immune aging?. Exp Gerontol. 2014;54:90-3. doi: 10.1016/j.exger.2014.01.003. [PubMed: 24440387].
Zhou H, Zhao H, Hao Y, Song C, Han J, Zhang J, et al. Excessive conversion and impaired thymic output contribute to disturbed regulatory T-cell homeostasis in AIDS patients with low CD4 cell counts. AIDS. 2013;27(7):1059-69. doi: 10.1097/QAD.0b013e32835e2b99. [PubMed: 23299175].
Li A, Zhu W, Yin J, Huang X, Sun L, Hua W, et al. A preliminary study on the characteristics of Th1/Th2 immune response in cerebrospinal fluid of AIDS patients with cryptococcal meningitis. BMC Infect Dis. 2021;21(1):500. doi: 10.1186/s12879-021-06138-z. [PubMed: 34051748].